Physician profile
Paolo Moretti
NPI 1093968265
$7,773.41
in general payments reported to CMS, 2019-2025
12 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,697 · 2020: $126 · 2022: $70.80 · 2023: $1,340 · 2024: $286 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,100 · Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,100.00 |
| Food and Beverage | $779.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,356.86 | 2019-2024 | |
| Abbott Laboratories | $543.15 | 2019-2025 | Infinity |
| Teva Pharmaceuticals USA, INC. | $269.33 | 2019 | |
| Biotronik INC. | $138.71 | 2025 | |
| Neurocrine Biosciences, INC. | $136.47 | 2024 | Ingrezza |
| Mdd US Operations, LLC | $133.00 | 2019 | |
| Amneal Pharmaceuticals LLC | $126.64 | 2024-2025 | Crexont |
| Acorda Therapeutics, INC | $26.61 | 2019 | |
| Merz Pharmaceuticals, LLC | $22.74 | 2024 | Xeomin |
| Lundbeck LLC | $19.90 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paolo Moretti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.